Affimed N.V P / E
Was ist das P / E von Affimed N.V?
P / E von Affimed N.V. ist 0.00
Was ist die Definition von P / E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens je Aktie für die nächsten zwölf Monate.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P / E von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Affimed N.V
Was macht Affimed N.V?
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Unternehmen mit p / e ähnlich Affimed N.V
- Richland Resources International hat P / E von N/A
- Safeplus International hat P / E von N/A
- China Yanyuan Yuhui Natl Ed Grp hat P / E von N/A
- Acusphere hat P / E von N/A
- American Oriental Bioengineering hat P / E von N/A
- Gourmet Provisions International hat P / E von N/A
- Affimed N.V hat P / E von 0.00
- SEL Manufacturing hat P / E von 0.00
- China Zhong Qi Hldgs hat P / E von 0.00
- MedSmart hat P / E von 0.00
- Panbela Therapeutics hat P / E von 0.00
- Epic hat P / E von 0.00
- 2574 hat P / E von 0.00